| Predicting new molecular targets for known drugs MJ Keiser, V Setola, JJ Irwin, C Laggner, A Abbas, SJ Hufeisen, ... Nature 462 (7270), 175, 2009 | 2024 | 2009 |
| Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders K Thomas, B Malcolm, D Lastra Journal of Psychoactive Drugs, 2017 | 146 | 2017 |
| Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders L Nguyen, KL Thomas, BP Lucke-Wold, JZ Cavendish, MS Crowe, ... Pharmacology & therapeutics 159, 1-22, 2016 | 146 | 2016 |
| Serotonin toxicity of serotonergic psychedelics B Malcolm, K Thomas Psychopharmacology 239 (6), 1881-1891, 2022 | 144 | 2022 |
| Driving performance comparing older versus younger drivers S Doroudgar, HM Chuang, PJ Perry, K Thomas, K Bohnert, J Canedo Traffic injury prevention 18 (1), 41-46, 2017 | 141 | 2017 |
| Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review A Sarparast, K Thomas, B Malcolm, CS Stauffer Psychopharmacology 239 (6), 1945-1976, 2022 | 86 | 2022 |
| Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions KLH Thomas, VL Ellingrod Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (7 …, 2009 | 38 | 2009 |
| Curriculum in psychiatry and neurology for pharmacy programs JA Dopheide, JR Bostwick, LW Goldstone, K Thomas, R Nemire, ... American journal of pharmaceutical education 81 (7), 5925, 2017 | 34 | 2017 |
| Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database IV Cohen, T Makunts, R Abagyan, K Thomas Scientific Reports 11 (1), 5997, 2021 | 32 | 2021 |
| Surveys of substance use disorders education in US pharmacy programs K Thomas, AJ Muzyk Mental Health Clinician 8 (1), 14-17, 2018 | 32 | 2018 |
| P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects MJ Bly, JR Bishop, KLH Thomas, VL Ellingrod Journal of sex & marital therapy 39 (3), 280-288, 2013 | 29 | 2013 |
| H., Edwards, DD, Shoichet, BK & Roth, BL 2009. Predicting new molecular targets for known drugs MJ Keiser, V Setola, JJ Irwin, C Laggner, AI Abbas, SJ Hufeisen, ... Nature 462 (7270), 175-181, 0 | 29 | |
| Substance use education in US schools of pharmacy: a systematic review of the literature AJ Muzyk, E Peedin, J Lipetzky, H Parker, MP McEachern, K Thomas Substance Abuse 38 (4), 455-463, 2017 | 27 | 2017 |
| Effects of valerian on subjective sedation, field sobriety testing and driving simulator performance K Thomas, J Canedo, PJ Perry, S Doroudgar, I Lopes, HM Chuang, ... Accident Analysis & Prevention 92, 240-244, 2016 | 26 | 2016 |
| Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia BA English, K Thomas, J Johnstone, A Bazih, L Gertsik, L Ereshefsky Biomarkers in Medicine 8 (1), 29-49, 2014 | 19 | 2014 |
| Clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid KL Thomas, Y Jiang, JS McCombs Annals of Clinical Psychiatry 27 (2), 90-99, 2015 | 18 | 2015 |
| A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic … KLH Thomas, VL Ellingrod, JR Bishop, MJ Keiser Psychopharmacology bulletin 43 (1), 11, 2010 | 15 | 2010 |
| The effects of dextromethorphan on driving performance and the standardized field sobriety test PJ Perry, K Fredriksen, S Chew, EJ Ip, I Lopes, S Doroudgar, K Thomas Journal of forensic sciences 60 (5), 1258-1262, 2015 | 14 | 2015 |
| Concomitant calcium channel blocker and antipsychotic therapy in patients with schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data P Van Dyke, KL Thomas Annals of Clinical Psychiatry 30 (1), 6-16, 2018 | 10 | 2018 |
| Adverse effects K Thomas, B Malcolm Handbook of medical hallucinogens, 414-438, 2021 | 7 | 2021 |
Michael J KeiserAssociate Professor, UCSFVerified email at ucsf.edu
